ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills

Jason Mast

Editor

In the three-company race to develop a new uterine fibroid treatment, ObsEva long lagged behind AbbVie and Myovant. Still, they hoped that better efficacy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills

Jason Mast

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

At least seven drugmakers say they will participate in round two of IRA negotiations

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Bipartisan 'pill penalty' fix and other bills vie for inclusion in reconciliation package

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

How AI can address ongoing challenges in the life sciences industry

Ob­sE­va’s sec­ond uter­ine fi­broids PhI­II comes through, send­ing some in­vestors to the hills

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills